RT Journal Article
T1 Adherence to mediterranean diet and the risk of differentiated thyroid cancer in a European cohort: The EPIC study.
A1 Llaha, Fjorida
A1 Cayssials, Valerie
A1 Farras, Marta
A1 Agudo, Antonio
A1 Sandström, Maria
A1 Eriksen, Anne Kirstine
A1 Tjønneland, Anne
A1 Boutron-Ruault, Marie-Christine
A1 Laouali, Nasser
A1 Truong, Therese
A1 Le Cornet, Charlotte
A1 Katzke, Verena
A1 Schulze, Matthias
A1 Palli, Domenico
A1 Krogh, Vittorio
A1 Signoriello, Simona
A1 Tumino, Rosario
A1 Ricceri, Fulvio
A1 Skeie, Guri
A1 Jensen, Torill Miriam Enget
A1 Chen, Sairah Lai Fa
A1 Lasheras, Cristina
A1 Rodriguez-Barranco, Miguel
A1 Amiano, Pilar
A1 Huerta, José María
A1 Guevara, Marcela
A1 Almquist, Martin
A1 Nilson, Lena Maria
A1 Hennings, Joakim
A1 Papier, Keren
A1 Heath, Alicia
A1 Weiderpass, Elisabete
A1 Rinaldi, Sabina
A1 Zamora-Ros, Raul
K1 EPIC study
K1 Mediterranean diet (MD)
K1 cohort
K1 intake
K1 meat
K1 thyroid cancer (TC)
AB The Mediterranean diet (MD) has been proposed as a healthy diet with a potential to lower the incidence of several types of cancer, but there is no data regarding thyroid cancer (TC). We investigated the association between MD adherence, and its components, and the differentiated TC risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Over 450,000 men and women from nine European countries were followed up for a mean of 14.1 years, during which 712 differentiated TC cases were identified. Adherence to MD was estimated using the relative MD (rMED) score, an 18-point scale including alcohol, and the adapted rMED (arMED) score, a 16-point scale excluding alcohol. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models adjusted for potential confounding factors. Adherence to the arMED score was not associated with the risk of differentiated TC (HRhigh vs. low adherence = 0.94, 95% CI: 0.70-1.25; p-trend 0.27), while a suggestive, but non-statistically significant inverse relationship was observed with rMED (HRhigh vs. low adherence = 0.88, 95% CI: 0.68-1.14; p-trend 0.17). Low meat (HRlow vs. high meat intake = 0.81, 95% CI: 0.67-0.99; p-trend = 0.04) and moderate alcohol (HRmoderate vs. non-moderate intake = 0.88, 95% CI: 0.75-1.03) intake were related with lower differentiated TC risk. Our study shows that a high adherence to MD is not strongly related to differentiated TC risk, although further research is required to confirm the impact of MD and, especially, meat intake in TC risk.
PB Frontiers Research Foundation
SN 2296-861X
YR 2022
FD 2022-08-09
LK http://hdl.handle.net/10668/20674
UL http://hdl.handle.net/10668/20674
LA en
NO Llaha F, Cayssials V, Farràs M, Agudo A, Sandström M, Eriksen AK, et al. Adherence to mediterranean diet and the risk of differentiated thyroid cancer in a European cohort: The EPIC study. Front Nutr. 2022 Sep 2;9:982369.
NO This research was funded by the Instituto de Salud Carlos III through the grant CP15/00100 (Co-funded by European Regional Development Fund. ERDF, a way to build Europe).The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, whichhas additional infrastructure support provided by the NIHR Imperial Biomedical Research Center (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de laSanté et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DifE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul CancroAIRC-Italy, Compagnia di San Paolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (ZorgOnderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) – Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology – ICO(Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPICNorfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom).We thank the CERCA Program/Generalitat de Catalunya for the institutional support to Bellvitge Biomedical Research Institute (IDIBELL). RZ-R. was supported by the Miguel Servet program (CPII20/00009) from the Institute of Health Carlos III [Cofunded by the European Social Fund (ESF) – ESF investing in your future].
DS RISalud
RD Apr 13, 2025